Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies.
Soluble glycoprotein V (sGPV) is a new plasma marker of thrombosis released from the platelet surface by thrombin. sGPV levels are increased in patients with atherothrombotic diseases, but the determinants of sGPV levels are unknown in the general population. Identification of these potential confounding factors is needed for correct design and analysis of clinical studies on cardiovascular diseases. The aim of this study was to determine the normal range of plasma values and the factors controlling sGPV levels in a population of normal individuals. Three hundred blood donors were recruited at the Etablissement Français du Sang-Alsace for the measurement of plasma levels of sGPV, platelet factor 4 (PF4), thrombin-antithrombin complexes (TAT) and D-dimers. The plasma level of sGPV was (median [interquartile range]) 27.5 [23.5-34.4] microg/l and displayed a Gaussian distribution. sGPV had a lower interindividual coefficient of variation (33%) than PF4 (176%), TAT (87%) or D-dimers (82%). sGPV levels were independent of age and sex but sensitive to red cell (r = 0.412; p < 0.0001) and platelet counts (r = 0.267; p = 0.001), total cholesterol (r = -0.313; p < 0.0001), food intake (r = 0.184; p = 0.0014) and smoking (r = -0.154; p = 0.039). Contrary to PF4 and TAT, sGPV did not differ between venous and arterial blood samples of 12 healthy individuals. Red cell and platelet counts, total cholesterol, current smoking and recent food intake are important determinants of sGPV levels and must be taken into account in clinical studies using sGPV as a thrombosis marker. Normal distribution of sGPV levels in the general population supports its use in clinical applications.
Aleil
Boris
B
EFS-Alsace, Strasbourg, France. boris.aleil@efs-alsace.fr
Meyer
Nicolas
N
Wolff
Valérie
V
Kientz
Daniel
D
Wiesel
Marie-Louise
ML
Gachet
Christian
C
Cazenave
Jean-Pierre
JP
Lanza
François
F
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D001782:Blood Donors; D002784:Cholesterol / Q000097:blood; D004906:Erythrocyte Count; D005215:Fasting / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D016011:Normal Distribution; D010447:Peptide Hydrolases / Q000032:analysis; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000032:analysis; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000032:analysis*; D012016:Reference Values; D012907:Smoking / Q000009:adverse effects; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis*
D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D019038:Platelet Glycoprotein GPIb-IX Complex; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D010978:Platelet Factor 4; D000990:Antithrombin III; D002784:Cholesterol; D010447:Peptide Hydrolases